A Phase III Randomized, Double Blind, Placebo Controlled, one way Crossover, Multi-Dose, Multi-center, Safety and Efficacy Study of T1h mAb administered intravenously in subjects with active moderate to severe psoriasis. Acronym TREAT-PLAQ.

Trial Profile

A Phase III Randomized, Double Blind, Placebo Controlled, one way Crossover, Multi-Dose, Multi-center, Safety and Efficacy Study of T1h mAb administered intravenously in subjects with active moderate to severe psoriasis. Acronym TREAT-PLAQ.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Itolizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms TREAT-PLAQ
  • Most Recent Events

    • 15 Mar 2011 Status changed from recruiting to active, no longer recruiting.
    • 15 Jun 2010 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India record.
    • 29 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top